Short-term treatment of the symptoms of gastroesophageal reflux disease (eg heartburn, regurgitation of stomach contents) in adults.
Composition:
1 tabl enteric contains 20 mg of pantoprazole.
Action:
A drug that inhibits the secretion of hydrochloric acid in the parietal cells of the stomach as a result of selective blocking of H activity+/ K+-ATP-azy (the so-called proton pump). The effect of the drug depends on the dose and leads to the inhibition of both basal secretion and stimulated secretion. It reduces the acidity of gastric contents and secondarily (in a reversible way) increases gastrin secretion to an extent proportional to the decrease in acidity. After oral administration, Pantoprazole is rapidly absorbed from the gastrointestinal tract, reaching a maximum concentration in the blood within 2 - 2.5 h. The bioavailability is about 77%, the food does not reduce the bioavailability, it can only delay the absorption of the drug. About 98% is bound to plasma proteins. It is metabolized in the liver, excreted in about 80% by the kidneys in the form of metabolites, the remaining part is excreted in the faeces. T0,5 is about 1.5 hours.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients. Co-administration with atazanavir.
Precautions:
It is not recommended for use in children and adolescents under 18 due to limited data on safety and efficacy. Caution should be exercised in patients: weight loss without intentional weight loss, anemia, gastrointestinal bleeding, dysphagia, persistent or bloody vomiting; with a history of peptic ulcer or gastrointestinal surgery; treated for indigestion or heartburn symptoms for more than 4 weeks; with jaundice, dysfunction or disease of the liver and other severe diseases affecting general well-being, as well as patients over 55 years who have experienced new symptoms or have changed the nature of previously observed symptoms. Before starting treatment, the cancerous nature of the disease should be excluded, as pantoprazole may mask the clinical picture and delay the diagnosis of cancer. Other proton pump inhibitors or histamine H receptor antagonists should not be used concurrently2. The use of the preparation may lead to a slight increase in the risk of gastrointestinal infections with bacteriaSalmonella, Campylobacter orC. difficile.
Pregnancy and lactation:
The product is not recommended during pregnancy and breast-feeding.
Side effects:
Uncommon: headache, dizziness; diarrhea, nausea, vomiting, feeling of fullness in the abdomen and bloating, constipation, dry mouth, pain and discomfort in the epigastrium; skin rash, erythema, skin eruptions, pruritus; weakness, tiredness and malaise; increased liver enzymes; sleep disorders. Rarely: blurred vision, blurred vision; urticaria, angioneurotic edema; painful joints, muscle pain; hyperlipidemias and increased lipid levels, weight change; increase in body temperature, peripheral edema; hypersensitivity (including anaphylactic reactions and anaphylactic shock); increase in bilirubin; depression (and worsening of the mental state). Very rare: thrombocytopenia, leukopenia; disorientation (and deterioration of mental state). Unknown: interstitial nephritis; Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, hypersensitivity to light; hyponatremia; liver cell damage, jaundice, hepatic cell failure; hallucinations, confusion (especially in susceptible patients as well as the severity of similar symptoms in case of their previous occurrence).
Dosage:
Orally. Adults. The recommended dose is 20 mg once a day, before a meal. In order to relieve symptoms, it may be necessary to use the medicine for the Next 2-3 days. After complete relief of symptoms, treatment should be discontinued. Treatment should not last longer than 4 weeks.No dosage adjustment is necessary for elderly patients or patients with renal or hepatic impairment. Table. do not chew or chew.
(C)
